Defining the Functional Role of Mutations in Diffuse Large B cell Lymphoma
定义突变在弥漫性大 B 细胞淋巴瘤中的功能作用
基本信息
- 批准号:9040901
- 负责人:
- 金额:$ 51.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingB-Cell LymphomasB-LymphocytesCRISPR screenCell LineCellsClinicalClustered Regularly Interspaced Short Palindromic RepeatsDNA Sequence AlterationDiseaseEmployee StrikesExclusionFocal AdhesionsGene ExpressionGene Expression ProfilingGene MutationGenesGeneticGenetic EngineeringGenetic HeterogeneityGoalsHealthHeterogeneityHumanIn VitroIndividualKnockout MiceLinkLymphomaMalignant NeoplasmsMethodsMolecular ProfilingMutateMutationOutcomePathway interactionsPatientsPatternPlayProcessResearchRoleSamplingStructure of germinal center of lymph nodeSubgroupTestingVariantWorkclinical phenotypeclinically significantcohortcost effectiveexome sequencingin vivolarge cell Diffuse non-Hodgkin&aposs lymphomaloss of functionneoplastic cellnew therapeutic targetnext generation sequencingnovelnovel therapeuticstherapeutic targettumorwhole genome
项目摘要
DESCRIPTION (provided by applicant): Diffuse Large B-Cell Lymphoma (DLBCL) is the most common form of lymphoma, comprising nearly 30% of all lymphoma cases. DLBCL is both clinically and molecularly heterogeneous. While nearly half of the patients are cured with standard therapy, the majority of the remaining patients succumb to the disease. In this proposal, we develop several complementary approaches that allow us to connect the specific genetic mutations in lymphomas to their context-specific roles. We propose to define the association of individual alterations with outcome, while accounting for the genetic heterogeneity among tumors. We have previously identified GNA13 as a commonly mutated gene in germinal center derived lymphomas including a subset of DLBCLs. We further propose to define lymphoma-specific roles of GNA13, as well as other variants that will be identified with this larger sample cohort through in vitro and in vivo approaches.
描述(由申请人提供):弥漫性大B细胞淋巴瘤(DLBCL)是最常见的淋巴瘤形式,占所有淋巴瘤病例的近30%。DLBCL在临床上和分子上都是异质性的。虽然近一半的患者通过标准治疗治愈,但其余大多数患者死于疾病。在这项提案中,我们开发了几种互补的方法,使我们能够将淋巴瘤中的特定基因突变与其特定的作用联系起来。我们建议定义个体改变与结果的关联,同时考虑肿瘤之间的遗传异质性。我们以前已经确定GNA13作为一个常见的突变基因在生殖中心衍生的淋巴瘤,包括一个子集的DLBCL。我们进一步提出定义GNA13的淋巴瘤特异性作用,以及将通过体外和体内方法用该较大样本队列鉴定的其他变体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sandeep Dave其他文献
Sandeep Dave的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sandeep Dave', 18)}}的其他基金
Genetic Origins of Adverse Outcomes in African Americans with Lymphoma
非裔美国人淋巴瘤不良后果的遗传起源
- 批准号:
10587289 - 财政年份:2023
- 资助金额:
$ 51.05万 - 项目类别:
Clinical and Genetic Origins of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma
单形性上皮性肠 T 细胞淋巴瘤的临床和遗传起源
- 批准号:
10566317 - 财政年份:2023
- 资助金额:
$ 51.05万 - 项目类别:
Exome-wide screening for common mutations in lymphoma
淋巴瘤常见突变的全外显子组筛查
- 批准号:
8190377 - 财政年份:2011
- 资助金额:
$ 51.05万 - 项目类别:
Exome-wide screening for common mutations in lymphoma
淋巴瘤常见突变的全外显子组筛查
- 批准号:
8279186 - 财政年份:2011
- 资助金额:
$ 51.05万 - 项目类别:
相似海外基金
Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
- 批准号:
24K19213 - 财政年份:2024
- 资助金额:
$ 51.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
- 批准号:
23K15982 - 财政年份:2023
- 资助金额:
$ 51.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
- 批准号:
10606730 - 财政年份:2023
- 资助金额:
$ 51.05万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10566833 - 财政年份:2023
- 资助金额:
$ 51.05万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10987699 - 财政年份:2023
- 资助金额:
$ 51.05万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10541285 - 财政年份:2022
- 资助金额:
$ 51.05万 - 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10540952 - 财政年份:2022
- 资助金额:
$ 51.05万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10703446 - 财政年份:2022
- 资助金额:
$ 51.05万 - 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
- 批准号:
22K08497 - 财政年份:2022
- 资助金额:
$ 51.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10707312 - 财政年份:2022
- 资助金额:
$ 51.05万 - 项目类别: